{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:40:09Z","timestamp":1765885209540,"version":"3.48.0"},"reference-count":30,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,12,19]]},"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To systematically categorise cancer research investment awarded to United Kingdom (UK) institutions in the period 2000\u20132013 and to estimate research investment relative to disease burden as measured by mortality, disability-adjusted life years (DALYs) and years lived with disability (YLDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic analysis of all open-access data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting and participants<\/jats:title>\n                    <jats:p>Public and philanthropic funding to all UK cancer research institutions, 2000\u20132013.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Number and financial value of cancer research investments reported in 2013 UK pounds (UK\u00a3). Mortality, DALYs and YLDs data were acquired from the Global Burden of Disease Study. A compound metric was adapted to estimate research investment relative to disease burden as measured by mortality, DALYs and YLDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 4299 funded studies with a total research investment of \u00a32.4 billion. The highest fundings by anatomical sites were haematological, breast, prostate, colorectal and ovarian cancers. Relative to disease burden as determined by a compound metric combining mortality, DALYs and YLDs, gender-specific cancers were found to be highest funded\u2014the five sites that received the most funding were prostate, ovarian, breast, mesothelioma and testicular cancer; the least well-funded sites were liver, thyroid, lung, upper gastrointestinal (GI) and bladder. Preclinical science accounted for 66.2% of award numbers and 62.2% of all funding. The top five areas of primary research focus by funding were pathogenesis, drug therapy, diagnostic, screening and monitoring, women's health and immunology. The largest individual funder was the Medical Research Council. In combination, the five lowest funded site-specific cancers relative to disease burden account for 47.9%, 44.3% and 20.4% of worldwide cancer mortality, DALYs and YLDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Research funding for cancer is not allocated according to relative disease burden. These findings are in line with earlier published studies. Funding agencies and industry should openly document their research investments to improve better targeting of research investment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-013936","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T20:10:27Z","timestamp":1492719027000},"page":"e013936","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Investments in cancer research awarded to UK institutions and the global burden of cancer 2000\u20132013: a systematic analysis"],"prefix":"10.1136","volume":"7","author":[{"given":"Mahiben","family":"Maruthappu","sequence":"first","affiliation":[{"name":"Epidemiology and Public Health, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G","family":"Head","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Global Health Research Institute, Institute for Life Sciences, University of Southampton, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie D","family":"Zhou","sequence":"additional","affiliation":[{"name":"Medical Sciences Division, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barnabas J","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Harvard University, Cambridge, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majd A","family":"El-Harasis","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalind","family":"Raine","sequence":"additional","affiliation":[{"name":"Department of Applied Health Research, UCL, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R","family":"Fitchett","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rifat","family":"Atun","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,4,20]]},"reference":[{"key":"2025121603361991000_7.4.e013936.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"2025121603361991000_7.4.e013936.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20107"},{"key":"2025121603361991000_7.4.e013936.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21262"},{"key":"2025121603361991000_7.4.e013936.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70442-X"},{"key":"2025121603361991000_7.4.e013936.5","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-11-0650"},{"key":"2025121603361991000_7.4.e013936.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70261-X"},{"key":"2025121603361991000_7.4.e013936.7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ebiom.2015.12.016","article-title":"Research investments in global health: a systematic analysis of UK infectious disease research funding and global health metrics, 1997-2013","volume":"3","author":"Head","year":"2016","journal-title":"EBioMedicine"},{"key":"2025121603361991000_7.4.e013936.8","doi-asserted-by":"publisher","DOI":"10.1186\/s12961-015-0052-5"},{"key":"2025121603361991000_7.4.e013936.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61340-X"},{"key":"2025121603361991000_7.4.e013936.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60692-4"},{"key":"2025121603361991000_7.4.e013936.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61689-4"},{"key":"2025121603361991000_7.4.e013936.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61728-0"},{"key":"2025121603361991000_7.4.e013936.13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bjc.6602321","article-title":"Years of life lost (YLL) from cancer is an important measure of population burden\u2014and should be considered when allocating research funds","volume":"92","author":"Burnet","year":"2005","journal-title":"Br J Cancer"},{"key":"2025121603361991000_7.4.e013936.14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12961-015-0050-7","article-title":"An analysis of discrepancies between United Kingdom cancer research funding and societal burden and a comparison to previous and United States values","volume":"13","author":"Carter","year":"2015","journal-title":"Heal Res Policy Syst"},{"key":"2025121603361991000_7.4.e013936.15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-526"},{"key":"2025121603361991000_7.4.e013936.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70759-8"},{"key":"2025121603361991000_7.4.e013936.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.03.024"},{"key":"2025121603361991000_7.4.e013936.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00223-5"},{"key":"2025121603361991000_7.4.e013936.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906173402406"},{"key":"2025121603361991000_7.4.e013936.20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1590\/S1135-57272009000100011","article-title":"Relationship between research funding in the Spanish national health system and the burden of disease","volume":"83","author":"Catal\u00e1 L\u00f3pez","year":"2009","journal-title":"Rev Esp Salud Publica"},{"key":"2025121603361991000_7.4.e013936.21","doi-asserted-by":"crossref","first-page":"648","DOI":"10.5694\/j.1326-5377.2009.tb03365.x","article-title":"Rational allocation of Australia's research dollars: does the distribution of NHMRC funding by National Health Priority Area reflect actual disease burden?","volume":"191","author":"Mitchell","year":"2009","journal-title":"Med J Aust"},{"key":"2025121603361991000_7.4.e013936.22","first-page":"83","article-title":"Association between the burden of disease and research funding by the Medical Research Council of Canada and The National Institutes of Health. A cross-sectional study","volume":"24","author":"Lamarre-Cliche","year":"2001","journal-title":"Clin Invest Med"},{"key":"2025121603361991000_7.4.e013936.23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1741-7015-12-99","article-title":"Estimating the returns to UK publicly funded cancer-related research in terms of the net value of improved health outcomes","volume":"12","author":"Glover","year":"2014","journal-title":"BMC Med"},{"key":"2025121603361991000_7.4.e013936.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006648"},{"key":"2025121603361991000_7.4.e013936.25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12916-016-0564-z","article-title":"Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom","volume":"14","author":"Sussex","year":"2016","journal-title":"BMC Med"},{"key":"2025121603361991000_7.4.e013936.26","unstructured":"Teperek M . In conversation with Wellcome Trust and Cancer Research UK. Published Online First: 2016. https:\/\/unlockingresearch.blog.lib.cam.ac.uk\/?p=528"},{"key":"2025121603361991000_7.4.e013936.27","unstructured":"Teperek M . Charities\u2019 perspective on research data management and sharing. Published Online First: 2016. https:\/\/unlockingresearch.blog.lib.cam.ac.uk\/?p=525"},{"key":"2025121603361991000_7.4.e013936.28","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0140-6736(16)31427-1","article-title":"Transparency and availability of data for cancer research","volume":"388","author":"Fitchett","year":"2016","journal-title":"Lancet"},{"key":"2025121603361991000_7.4.e013936.29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S2213-8587(16)00037-1","article-title":"Liberating data: the crucial weapon in the fight against NCDs","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025121603361991000_7.4.e013936.30","unstructured":"CRUK. Annual report and accounts 2014\/15. 2015. http:\/\/www.cancerresearchuk.org\/sites\/default\/files\/annual_report_and_accounts_2014-15.pdf"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-013936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:36:27Z","timestamp":1765884987000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-013936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4,20]]},"published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1136\/bmjopen-2016-013936"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-013936","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}